Brief: Innate Pharma: First Patient Dosed In Clinical Trial In Blood Cancers

Innate Pharma SA

16/12/2021 06:06

Dec 16 (Reuters) - INNATE PHARMA SA  IPH.PA :
    * INNATE PHARMA: FIRST PATIENT DOSED IN IPH6101/SAR443579
PHASE
1/2 CLINICAL TRIAL IN VARIOUS BLOOD CANCERS
    * PARTNER SANOFI ADVANCES IPH6101/ SAR443579, A NOVEL
NKP46/CD16-BASED, CD123 TARGETED NK CELL ENGAGER, TO
FIRST-IN-HUMAN CLINICAL TRIAL IN RELAPSED/REFRACTORY AML, B-ALL
OR HR-MDS
    * FIRST MOLECULE FROM INNATE'S MULTI-SPECIFIC NK CELL
ENGAGER
PLATFORM, ANKET(TM), TO PROGRESS TO CLINIC

Source text for Eikon:  ID:nBw3L5dvCa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))